FDA Gives Priority Review to Roche’s Kidney Disease Therapy
Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro…
Read More...
Read More...
